Incyte CMO and Head of Late-Stage Development Steven H. Stein reports $28.44 million common-share disposal

• Incyte's chief medical officer and head of late-stage development, Steven H. Stein, sold 240,193 common shares on November 6, 2026.
• Sales carried weighted-average prices ranging from $116.0632 to $119.6639 per share.
• Stein also exercised options for 240,193 common shares at exercise prices ranging from $61.18 to $113.64.
• The November 10, 2026, filing reported remaining direct beneficial ownership of 30,916 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incyte Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001673776-26-000022), on November 10, 2026, and is solely responsible for the information contained therein.